派林生物：关于全资子公司获得药品补充申请受理通知书的公告

Core Viewpoint - Recently, the company announced that its wholly-owned subsidiary, Guangdong Shuanglin Biopharmaceutical Co., Ltd., received a notice of acceptance for a supplemental application for intravenous human immunoglobulin from the National Medical Products Administration [2] Group 1 - The company has made progress in its product development by receiving regulatory approval for a key drug [2] - The approval is expected to enhance the company's product portfolio and market position in the biopharmaceutical industry [2]